OBJECTIVES

: The objective of this analysis was to assess and compare the long term cost per responder (CPR) based on the American College of Rheumatology (ACR) outcomes following 48 weeks of treatment with Secukinumab (SEC150mg, SEC 300mg) relative to Adalimumab (ADA, anti TNF) for the treatment of Psoriatic Arthritis (PsA) in Tunisia.

METHODS

: The CPR for each treatment namely Secukinumab and Adalimumab was calculated by dividing the acquisition cost of each drug by its response rate. Drug costs were estimated based on the Tunisian Central Pharmacy (PCT) database (currency in TND) and the number of doses required during 48 weeks. The long-term response rates were applied from a matching-adjusted indirect comparison (MAIC) technique based on the data from FUTURE2 and ADEPT clinical trials of Secukinumab and Adalimumab respectively. MAIC analysis matched patient populations on key baseline characteristics.

RESULTS

: MAIC analysis showed that ACR (20/50/70) response rates were significantly higher for SEC150mg and SEC300mg compared to ADA at 48 weeks.

ACR 20 response rates were 80%, 74% and 56%, ACR 50 response rates were 57%, 61% and 44% whereas the ACR 70 response rates were 32%, 43% and 30% for SEC 150mg, SEC 300 mg and ADA respectively.

SEC has a lower CPR compared to ADA among PsA patients. Cost per ACR 20 responder were TND29,523.00, TND63,935.00 and TND65,712.00, cost per ACR50 responder were TND41,141.00, TND 76,547.00 and TND84,630.00 whereas costs per ACR 70 responder were TND72,641.00, TND109,591.00 and TND124,124.00 for SEC 150mg, SEC 300mg and ADA respectively.

CONCLUSIONS

: These findings support the economic advantage of SEC over ADA in the treatment of PsA. With SEC, Tunisian PsA patient could be treated more efficiently compared to ADA.